Patients must have a thyroid-stimulating hormone (TSH) with reflex free T3/free T4 (if TSH is out of normal range) and electrocardiogram (EKG) obtained within 7 days prior to sub-study registration
Patients must have adequate thyroid function, as evidenced by either thyroid-stimulating hormone (TSH) or, free thyroxine (T4) serum tests demonstrating values within the normal range, within 28 days prior to registration; Note: TSH, with reflex T4 is allowable if per institutional standard; otherwise, both TSH and free-T4 must be obtained
Thyroid stimulating hormone (TSH) within normal limits (WNL); supplementation is acceptable to achieve a TSH WNL; in patients with abnormal TSH if free T4 is normal and patient is clinically euthyroid, patient is eligible
Re-registration: TSH WNL; supplementation is acceptable to achieve a TSH WNL; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
Thyroid-stimulating hormone (TSH) within normal limits (WNL); supplementation is acceptable to achieve a TSH WNL; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
Thyroid stimulating hormone (TSH) within normal limits (WNL); supplementation is acceptable to achieve a TSH WNL; in patients with abnormal TSH however if the Free T4 is normal and patient is clinically euthyroid, patient is eligible
A serum thyroid-stimulating hormone (TSH) must be obtained within 28 days prior to step 2 registration to obtain a baseline value
Thyroid-stimulating hormone (TSH) within normal limits (TSH < ULN allowed in euthyroid patients on thyroid replacement therapy)
Adequate organ function as defined by System Laboratory Values; Hematologic (Absolute neutrophil count [ANC] >=1.5x10^9/ liter [L], Lymphocyte count >1,000/cubic millimeter [mm^3], Hemoglobin >=9 grams/deciliter [g/dL], Platelets >=100x10^9/L), Hepatic (Total bilirubin <=1.5x upper limit of normal [ULN] [For subjects with Gilbert's Syndrome, only if direct bilirubin <=35%, <=3.0xULN], alanine aminotransferase [ALT] <=1.5xULN); Renal (Serum Creatinine <=1.5xULN OR Calculated creatinine clearance [CrCl >50 mL/min) and Endocrine (Thyroid stimulating hormone [TSH] within normal limits. If TSH is not within normal limits at baseline, the subject may still be eligible if total T3 or free T3 and free T4 are within the normal limits.
Any isolated laboratory abnormality suggestive of a serious autoimmune disease (e.g. hypothyroidism): antinuclear antibody, thyroid-stimulating hormone (TSH), free thyroxine (FT4), rheumatoid factor
Thyroid stimulating hormone (TSH) OR free thyroxine (T4) within the normal limits
Thyroid stimulating hormone (TSH) =< 1 x ULN.
Thyroid-stimulating hormone (TSH) WNL\r\n* Supplementation is acceptable to achieve a TSH WNL; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
Adequate thyroid function within 14 days prior to registration defined as serum thyroid-stimulating hormone (TSH) within the normal range
Normal serum TSH within 12 months preceding surgery
Patients may have had a recent previous hospital admission (within 30 days) or be admitted preoperatively but not for the following conditions\r\n* Unstable angina\r\n* Congestive heart failure\r\n* Severe hypothyroidism thyroid-stimulating hormone (TSH) >10\r\n** Endocrine consult and intervention may allow participation at the discretion of the principal investigator (PI) for a TSH > 10
Triiodothyronine measurement (T3), thyroxine (T4) or thyroid-stimulating hormone (TSH) =< 3.0 x IULN
Adequately controlled thyroid function, with no symptoms of thyroid dysfunction and thyroid stimulating hormone (TSH) within normal limits
Participants with DTC must be receiving thyroxine suppression therapy and levels of thyroid stimulating hormone (TSH) should not be elevated (TSH should be less than or equal to 5.50 milliunits per liter (mU/L)). When tolerated by the participant, thyroxine dose should be changed to achieve TSH suppression (TSH less than 0.50 mU/L).
Thyroid-stimulating hormone (TSH) and free thyroxine (T4) within normal limits (patients may be on thyroid hormone replacement)
A serum thyroid-stimulating hormone (TSH), free T4, and AM (morning) cortisol must be obtained within 14 days prior to randomization to obtain a baseline value and be within normal limits for the local laboratory
Thyroid stimulating hormone (TSH) within normal limits
Adequately controlled thyroid function, with no symptoms of thyroid dysfunction and thyroid-stimulating hormone (TSH) within normal limits
Normal thyroid function testing (thyroid stimulating hormone [TSH]) within 14 days prior to registration
Thyroid-stimulating hormone (TSH) up to 4 times ULN if thyroxine (T4) is normal
Thyroid-stimulating hormone (TSH) within institutional/laboratory normal limits
Thyroid stimulating hormone (TSH) within institutional normal range – patients with thyroid disease are eligible if euthyroid on suppressive or replacement therapy
Thyroid-stimulating hormone (TSH) within normal limits (WNL); supplementation is acceptable to achieve a TSH WNL; in patients with abnormal TSH however free T4 and free thyroxine index (FTI) are normal and patient is clinically euthyroid, patient is eligible
Thyroid stimulating hormone (TSH) within normal limits
Normal (=< upper limit of normal) levels of thyroid stimulating hormone (TSH), free T4, adrenocorticotropic hormone (ACTH), morning AM cortisol, amylase and lipase are required for entry to cohorts 4, 5 and 6 (AM cortisol testing may be taken up to 5 pm per Moffit Cancer Center guidelines)
Patients should have normal baseline thyroid-stimulating hormone (TSH); patients with elevated TSH level (between 4.5-10 mU/L in the absence of symptoms of hypothyroidism) must have a normal free thyroxine (T4); TSH that is 10 mU/L or higher is exclusionary\r\n* A history of hypothyroidism and/or hyperthyroidism is allowed, as long as the patient has stable well-controlled thyroid function for a minimum of 2 months
Thyroid stimulating hormone (TSH) within institutional limits (ie: normal); if TSH is greater or less than institutional limits patients may participate if their T4 is within normal limits (WNL); patients may be on a stable dose of replacement thyroid medication; dose adjustments are allowed if needed
Adequate thyroid function within 28 days prior to registration defined as serum thyroid-stimulating hormone (TSH) in normal range
Thyroid-stimulating hormone (TSH) (0.3-5.0) and free thyroxine (0.8-1.87) within Mayo normal range
Uncompensated hypothyroidism (defined as thyroid-stimulating hormone [TSH] greater than 2 x upper limit of normal not treated with replacement hormone)
Adequately controlled thyroid function, with no symptoms of thyroid dysfunction and thyroid stimulating hormone (TSH) within normal limits
Patients must have a normal baseline thyroid stimulating hormone (TSH); a history of hypothyroidism and/or hyperthyroidism is allowed
Thyroid stimulating hormone (TSH) within institutional limits (i.e.: normal); if TSH is greater or less than institutional limits patients may participate if their T4 is within normal limits (WNL); patients may be on a stable dose of replacement thyroid medication; dose adjustments are allowed if needed (labs should be performed within 14 days of treatment initiation)
Uncontrolled hypothyroidism; patients must have a normal thyroid-stimulating hormone (TSH) per institutional standards at baseline
Thyroid stimulating hormone (TSH) within normal limits (WNL); medications for thyroid dysfunction are allowed as long as TSH is normal at registration; in patients with abnormal TSH, if the free thyroxine (free T4) and free thyroxine index (FTI) are normal and patient is clinically euthyroid, patient is eligible
Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity; hypothyroidism treated with medication is not excluded if thyroid-stimulating hormone (TSH) is within normal limits
The patient has normal thyroid function tests (thyroid-stimulating hormone [TSH], free T4) as defined by the testing laboratory, a test abnormality that is asymptomatic and does not warrant medical intervention, or a pre-existing thyroid disorder that is controlled on medical treatment
Thyroid-stimulating hormone (TSH) >= LLN and free T4 within normal limits; patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism; the thyroid supplement dose must be a stable dose for at least one month prior to study enrollment
Performed within 10 days of treatment initiation: Thyroid stimulating hormone (TSH) within institutional limits (ie: normal); if TSH is greater or less than institutional limits patients may participate if their thyroxine (T4) is within normal limits (WNL); patients may be on a stable dose of replacement thyroid medication; dose adjustments are allowed if needed
Uncontrolled hypothyroidism defined as serum thyroid stimulating hormone (TSH) higher than 5 mIU/mL while receiving appropriate thyroid hormone therapy
Adequate thyroid-stimulating hormone (TSH) suppression (< 0.5 mIU/L)
Normal thyroid function (thyroid stimulating hormone [TSH] and free thyroxine [T4]) (clinically euthyroid patients are acceptable)
Thyroid stimulating hormone (TSH) within normal limits (WNL) (patients may be on thyroid hormone replacement)
Thyroid-stimulating hormone (TSH) within normal limits (WNL) \r\n* Supplementation is acceptable to achieve a TSH WNL; in patients with abnormal TSH if free T4 is normal and patient is clinically euthyroid, patient is eligible
Patients must have normal baseline thyroid function tests (thyroid stimulating hormone [TSH], triiodothyronine [T3], thyroxine [T4]); a history of hypothyroidism and/or hyperthyroidism is allowed, as long as the patient has stable well-controlled thyroid function for a minimum of 2 months
Abnormal thyroid-stimulating hormone (TSH)
Thyroid stimulating hormone (TSH) < 10 mIU/L
History of uncontrolled hypothyroidism as evidenced by thyroid test (thyroid-stimulating hormone [TSH]) within the last month, hypercalcemia or hyperglycemia (within the last 15 days)
Thyroid-stimulating hormone (TSH) within normal institutional limits
Thyroid stimulating hormone (TSH) =< 1.5 times ULN, within 30 days prior to enrollment
Thyroid stimulating hormone (TSH) 0.27 - 4.20 ulU/mL
Hyperthyroidism (thyroid-stimulating hormone [TSH] < 0.4 mIU/L and free T4 > 1.6 ng/dL)
Thyroid-stimulating hormone (TSH) ? 13 micro international units/mL
Thyroid-stimulating hormone (TSH) < 13 micro international units/mL
Prior bovine thyroid stimulating hormone (TSH) use
Thyroid-stimulating hormone (TSH) < 13 micro International units/mL
Thyroid-stimulating hormone (TSH) =< 10 micro international units/mL
Thyroid-stimulating hormone (TSH) < 13 micro international units/mL
Participants must be receiving thyroxine suppression therapy and thyroid stimulating hormone (TSH) should not be elevated (TSH should be ?5.50 mcIU/ML). When tolerated by the participant, thyroxine dose should be changed to achieve TSH suppression (TSH <0.50 mcIU/ML) and this dose may be changed concurrently upon starting study drug treatment.